Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1672
    +0.0016 (+0.13%)
     

  • GBP/USD

    1.2483
    -0.0028 (-0.22%)
     

  • Bitcoin GBP

    51,061.02
    -264.99 (-0.52%)
     

  • CMC Crypto 200

    1,321.81
    -74.72 (-5.35%)
     

  • S&P 500

    5,103.45
    +55.03 (+1.09%)
     

  • DOW

    38,250.16
    +164.36 (+0.43%)
     

  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     

  • GOLD FUTURES

    2,348.10
    +5.60 (+0.24%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Editas Medicine (EDIT) Gains As Market Dips: What You Should Know

Zacks Equity Research
·2-min read

In the latest trading session, Editas Medicine (EDIT) closed at $76.14, marking a +0.29% move from the previous day. This change outpaced the S&P 500's 0.72% loss on the day. Elsewhere, the Dow lost 0.57%, while the tech-heavy Nasdaq lost 0.87%.

Heading into today, shares of the genome editing company had gained 21.07% over the past month, outpacing the Medical sector's gain of 3.28% and the S&P 500's gain of 4.69% in that time.

Wall Street will be looking for positivity from EDIT as it approaches its next earnings report date. In that report, analysts expect EDIT to post earnings of -$0.82 per share. This would mark a year-over-year decline of 10.81%. Our most recent consensus estimate is calling for quarterly revenue of $6.80 million, down 44.65% from the year-ago period.

It is also important to note the recent changes to analyst estimates for EDIT. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

ADVERTISEMENT

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. EDIT is holding a Zacks Rank of #4 (Sell) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 209, which puts it in the bottom 19% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.